WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100665

CAS#: 95734-82-0

Description: Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy. It produces less nausea, vomiting and nephrotoxicity than other platinum-containing drugs. (Source:

Chemical Structure

CAS# 95734-82-0

Theoretical Analysis

MedKoo Cat#: 100665
Name: Nedaplatin
CAS#: 95734-82-0
Chemical Formula: C2H6N2O3Pt
Exact Mass: 303.018283
Molecular Weight: 301.16464
Elemental Analysis: C, 7.98; H, 2.01; N, 9.30; O, 15.94; Pt, 64.78

Size Price Shipping out time Quantity
10mg USD 310 2 Weeks
25mg USD 600 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-27. Prices are subject to change without notice.

Nedaplatin, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


IUPAC/Chemical Name: platinum, diammine(hydroxy-kappaO)acetato(2-)-kappaO)-, (SP-4-3)-


InChi Code: InChI=1S/C2H4O3.2H2N.Pt/c3-1-2(4)5;;;/h3H,1H2,(H,4,5);2*1H2;/q;2*-1;+2

SMILES Code: O=C([O-])CO.[NH2-].[NH2-].[Pt+2]

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 301.16464 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010 Jun 30. [Epub ahead of print] PubMed PMID: 20593091.

2: Miura T, Hosojima Y, Nakamura J, Yamada S, Nakazawa Y, Ozeki Y, Miura T, Yanagi M, Yamazaki H, Takahashi T. [An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance]. Gan To Kagaku Ryoho. 2010 May;37(5):883-5. Japanese. PubMed PMID: 20495320.

3: Zhang J, Wang L, Xing Z, Liu D, Sun J, Li X, Zhang Y. Status of bi- and multi-nuclear platinum anticancer drug development. Anticancer Agents Med Chem. 2010 May 1;10(4):272-82. PubMed PMID: 20184553.

4: Iijima S, Makari Y, Kato T, Ooshima S, Hoshi M, Doi T, Miyake Y, Sakamoto T, Kato A, Miyo M, Kurokawa E, Kikkawa N. [A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2052-4. Japanese. PubMed PMID: 20037320.

5: Zhang J, Liu D, Li Y, Sun J, Wang L, Zang A. Status of non-classical mononuclear platinum anticancer drug development. Mini Rev Med Chem. 2009 Oct;9(11):1357-66. Review. PubMed PMID: 19929810.

6: Alberto ME, Lucas MF, Pavelka M, Russo N. The second-generation anticancer drug Nedaplatin: a theoretical investigation on the hydrolysis mechanism. J Phys Chem B. 2009 Oct 29;113(43):14473-9. PubMed PMID: 19778071.

7: Nishime C, Ohnishi Y, Suemizu H, Tamaoki N, Kusumi T, Sato F, Yamazaki H, Nakamura M, Ueyama Y, Kijima H. In vivo chemotherapeutic profile of human gallbladder small cell carcinoma. Biomed Res. 2008 Oct;29(5):251-6. PubMed PMID: 18997440.

8: Tanaka T, Yukawa K, Umesaki N. Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro. Eur J Gynaecol Oncol. 2007;28(5):352-5. PubMed PMID: 17966212.

9: Loh GW, Ting LS, Ensom MH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet. 2007;46(6):471-94. Review. PubMed PMID: 17518507.

10: Xu RH, Shi YX, Guan ZZ, Jiang WQ, Huang H, Ma ZY, Wang JH, Hu XH, Xie WM, Li XG, Liu YL, Pan LX, Dai AD, Zhuang W, Zhang C. [Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma]. Ai Zheng. 2006 Dec;25(12):1565-8. Chinese. PubMed PMID: 17166388.

Additional Information

Nedaplatin is a second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. This agent appears to be less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)